PCSK9 and atherosclerosis: Two fully human monoclonal antibodies (mAbs) for inhibiting PCSK9, evolocumab and alirocumab, have been shown to reduce cardiovascular events in adult patients with ASCVD, and also LDL-C and other lipid parameters among pediatric patients with HeFH in randomized controlled trials (RCTs) [15,16,17,18].